Chemotherapy resistance mechanisms

Acta Oncologica

Volumn 35, Issue SUPPL. 5, 1996, Pages 76-80

  Ringborg, Ulrik ^a   Platz, Anton ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METALLOTHIONEIN; MULTIDRUG RESISTANCE PROTEIN;

BIOCHEMISTRY; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ALDEHYDE DEHYDROGENASE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENES, MDR; GENES, P53; HUMANS;

EID: 0030483452     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609083976     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 39: 1-15, 71-85.
2. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomised trial. J Clin Oncol 1995; 13: 2483-89.
3. Simon SM, Schindler M. Cell biological mechanisms of multi-drug resistance in tumours. Proc Natl Acad Sci USA 1994; 9: 3497-504.
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
5. Ling V, Carlsen SA, See YP. Altered drug permeability in mammalian cell mutants. Adv Exp Med Biol 1977; 84: 247-64.
6. Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multi-drug resistance. Nature (London) 1986; 323: 728-31.
7. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-08.
8. Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42: 4730-33.
9. Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdrl gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 1995; 87: 1593-602.
10. Eliason JF, Ramuz H, Kaufmann F. Human multi-drug-resistant cancer cells exhibit a high degree of selectivity for stereoisomers of verapamil and quinidine. Int J Cancer 1990; 46: 113-17.
11. Wishart GC, Bisset D, Paul J, Jodrell D, Harnett A, Tabeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994; 12: 1771-77.
12. Merkel DE, Fuqua SAW, Tandom AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression of gene amplification. J Clin Oncol 1989; 7: 1129-36.
13. Schneider J, Bak M, Efferth T, Kaufmann M. Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989; 60: 815-18.
14. Goldstein LJ, Galshi H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
15. Ciaccio PJ, Tew KD, LaCreta FP. Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. Biochem Pharmacol 1991; 42: 1504-07.
16. Berhane K, Hao X-Y, Egyházi S, Hansson J, Ringborg U, Mannervik B. Contribution of glutathione transferase M3-3 to 1,3-Bis(2-chloroethyl)-1-nitroso-urea resistance in a human non-small cell lung cancer cell line. Cancer Res 1993; 53: 4257-61.
17. Shea TC, Kelley SL, Henner WD. Identification of an anionic form of glutathione transferase present in many human tumors and human tumor cell lines. Cancer Res 1988; 48: 527-33.
18. Levy E, Baroche C, Barret JM, et al. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis 1994; 15: 845-50.
19. Platz A, Jungnelius U, Grafström E, Lagerlöf B, Mannervik B, Ringborg U. Glutathione transferase P1-1 expression in human melanoma metastases. Acta Oncol 1995; 34: 759-65.
20. Broxterman HJ, Giaccone G, Lankelma J. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Current Opinion in Oncology 1995; 7: 532-40.
21. Müller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-37.
22. Lutzky J, Astor MB, Taub RN. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res 1989; 49: 4120-25.
23. Zaman GJ, Lankelma J, van Tellingen O, et al. Role of glutathione in the export of compounds from cells by the multidrug resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-94.
24. Goulding H, Jasani B, Pereira H, et al. Metallothionein expression in human breast cancer. Br J Cancer 1995; 72: 968-72.
25. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44: 5156-60.
26. Andersson B, Mroue M, Britten RA, Murray D. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res 1994; 54: 5394-400.
27. Kim R. Hirabayashi N, Nishiyama M, et al. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 1991; II: 429-31.
28. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8: 933-38.
29. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-29.
30. Hotta T, Saito Y, Fujita H, et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994; 21: 135-40.
31. Preuss I, Eberhagen I, Haas S, et al. O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 1995; 61: 321-26.
32. Hoeijmakers JHJ. Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer 1994; 30A: 1912-21.
33. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26.
34. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
35. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
36. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multi-factorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57: 1-9.
37. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74: 63-68.
38. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1: 1-6.
39. Jansson T, Inganäs M, Sjögren S, et al. p53 status predicts survival in breast cancer patients treated with/without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995; 13: 1470-77.
40. Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994; 54: 2986-90.
41. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth M. Sensitive detection of an occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-82.
42. -7. Proc Natl Acad Sci USA 1995; 92: 537-41.